Confirmational Proteomics- Is It Time?

Recorded On: 12/21/2022

Once a diagnosis of cancer has been established, the tissue specimen containing tumor may be referred for molecular testing (e.g., DNA and RNA sequencing) to detect genomic alterations that can select patients for targeted therapy. However, will these targeted treatments be effective? “Confirmational Proteomics” is an application of immunohistochemistry that can evaluate the tumor “landscape” for overexpression or loss of specific proteins associated with genomic alterations, and which may help guide therapy for patients with certain types of cancer.

Presented by Dr. Richard Cartun, MD

Richard Cartun, MS, PhD

Director, Histology/Morphologic Proteomics

Hartford Hospital

Dr. Cartun was the Director of Histology, Immunopathology, and the Martin M. Berman, MD Morphologic Proteomics Laboratory at Hartford Hospital, a large tertiary care hospital in Hartford, CT. He was leading immunohistochemical testing for more than 40 years now and, as a result, have extensive knowledge in the technical aspects and interpretation of this valuable laboratory test.